Mikael Dolsten M.D., Ph.D.
Net Worth
Last updated:
What is Mikael Dolsten M.D., Ph.D. net worth?
The estimated net worth of Dr. Mikael Dolsten M.D., Ph.D. is at least $51,820,013 as of 7 Nov 2022. He owns shares worth $8,426,886 as insider, has earned $11,893,127 from insider trading and has received compensation worth at least $31,500,000 in Pfizer Inc..
What is the salary of Mikael Dolsten M.D., Ph.D.?
Dr. Mikael Dolsten M.D., Ph.D. salary is $4,500,000 per year as Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical in Pfizer Inc..
How old is Mikael Dolsten M.D., Ph.D.?
Dr. Mikael Dolsten M.D., Ph.D. is 67 years old, born in 1958.
What stocks does Mikael Dolsten M.D., Ph.D. currently own?
As insider, Dr. Mikael Dolsten M.D., Ph.D. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Pfizer Inc. (PFE) | Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical | 333,342 | $25.28 | $8,426,886 |
What does Pfizer Inc. do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Mikael Dolsten M.D., Ph.D. insider trading
Pfizer Inc.
Dr. Mikael Dolsten M.D., Ph.D. has made 12 insider trades between 2018-2022, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 199,548 units of PFE stock on 11 Nov 2021. As of 7 Nov 2022 he still owns at least 333,342 units of PFE stock.
Pfizer key executives
Pfizer Inc. executives and other stock owners filed with the SEC:
- Dr. Albert Bourla D.V.M., DVM, Ph.D. (63) Chairman & Chief Executive Officer
- Dr. Mikael Dolsten M.D., Ph.D. (67) Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical
- Mr. John D. Young (60) Advisor
- Ms. Angela Hwang (59) Group Pres of Biopharmaceuticals Group